A similar Nrf2 activator, CDDO-Im, was previously tested in a non-tumor bearing, high single dose mouse model of cisplatin-induced AKI and resulted in increased Nrf2 signaling in the kidneys and protection from cisplatin nephrotoxicity as measured by changes in blood urea nitrogen and renal histopathology (Aleksunes et al. 2010). Here, NFE2L2 is linked to neoplasm.